107 related articles for article (PubMed ID: 1682042)
1. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
Gautam SC; Chikkala NF; Ganapathi R; Hamilton TA
Cancer Res; 1991 Nov; 51(22):6133-7. PubMed ID: 1682042
[TBL] [Abstract][Full Text] [Related]
2. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Amagai Y; Matsumoto M; Hojo K; Iguchi M; Wada T; Tanaka H; Ide N; Kato A; Shichijo M; Abe K
Jpn J Clin Oncol; 2010 Jun; 40(6):503-7. PubMed ID: 20106881
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
6. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
9. [Antitumor activity of UFT against murine renal cell carcinoma: a study on the suppression tumor metastases].
Fujioka T; Hasegawa M; Ishikura K; Nomura K; Okamoto T; Tanji S; Koike H; Kubo T
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2031-6. PubMed ID: 2221926
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity.
Wang L; Qi X; Sun Y; Liang L; Ju D
Cancer Gene Ther; 2002 Oct; 9(10):819-24. PubMed ID: 12224022
[TBL] [Abstract][Full Text] [Related]
11. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
12. [Synergistic role between rhIL-2 and adriamycin long circulating temperature-sensitive liposome in targeting therapy on tumor].
Dong LF; Mei HS; Song SX; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):296-300. PubMed ID: 15862144
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of the new vinca-alkaloid S 12363 alone or in combination with verapamil on a human multidrug resistant renal carcinoma xenograft.
Berlion M; Arvelo F; Leonce S; Bourgeois Y; Rigaudy P; Bizzari JP; Poupon MF
In Vivo; 1993; 7(5):399-405. PubMed ID: 7906553
[TBL] [Abstract][Full Text] [Related]
16. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effect of murine renal cell carcinoma cells genetically modified to express B7-1 combined with cytokine secreting fibroblasts.
Wang J; Nakamoto T; Kasaoka Y; Usui T; Hamada H
Hiroshima J Med Sci; 2000 Mar; 49(1):73-82. PubMed ID: 10824460
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of natural killer activity, induction of IFN and development tumor immunity during the successful treatment of established murine renal cancer using flavone acetic acid and IL-2.
Hornung RL; Back TC; Zaharko DS; Urba WJ; Longo DL; Wiltrout RH
J Immunol; 1988 Nov; 141(10):3671-9. PubMed ID: 2460546
[TBL] [Abstract][Full Text] [Related]
19. Development of a safe and effective adriamycin plus interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas.
Ho RL; Maccubbin D; Zaleskis G; Krawczyk C; Wing K; Mihich E; Ehrke MJ
Oncol Res; 1993; 5(9):373-81. PubMed ID: 8038458
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.
Salup RR; Back TC; Wiltrout RH
J Immunol; 1987 Jan; 138(2):641-7. PubMed ID: 3491854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
